These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 31164525)

  • 1. [FOLFIRINOX for Locally Advanced and Recurrent Pancreatic Cancer with UGT1A1 *6 and or UGT1A1*28 Polymorphisms-A Report of Two Cases].
    Ishigame T; Kimura T; Tsukida S; Suzushino S; Muto M; Sato N; Kofunato Y; Okada R; Kenjo A; Shimura T; Marubashi S
    Gan To Kagaku Ryoho; 2019 Apr; 46(4):754-756. PubMed ID: 31164525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
    Umemoto K; Takahashi H; Morizane C; Yamada I; Shimizu S; Shioji K; Yoshida Y; Motoya M; Mizuno N; Kojima Y; Terashima T; Uesugi K; Ueno M; Furuse J; Akimoto T; Ikeda M
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):397-404. PubMed ID: 33386925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
    Shirasu H; Todaka A; Omae K; Fujii H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Kobayashi M; Fukutomi A
    Cancer Sci; 2019 Feb; 110(2):707-716. PubMed ID: 30447099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
    Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL
    Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.
    Yang C; Liu Y; Xi WQ; Zhou CF; Jiang JL; Ma T; Ye ZB; Zhang J; Zhu ZG
    Drug Des Devel Ther; 2015; 9():3677-83. PubMed ID: 26229432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
    Yokokawa A; Kaneko S; Endo S; Minowa Y; Ayukawa H; Hirano R; Nagashima F; Naruge D; Okano N; Kobayashi T; Kawai K; Furuse J; Furuta T; Shibasaki H
    Eur J Drug Metab Pharmacokinet; 2021 Mar; 46(2):317-324. PubMed ID: 33619631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of UGT1A1 polymorphisms on modified FOLFIRINOX dose in double-variant-type patients with advanced pancreatic cancer.
    Satake T; Morizane C; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Ueno H; Okusaka T
    Int J Clin Oncol; 2022 Aug; 27(8):1331-1339. PubMed ID: 35637361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
    Kobayashi N; Omae K; Horita Y; Ueno H; Mizuno N; Uesugi K; Sudo K; Ozaka M; Hayashi H; Okano N; Kamei K; Yamaguchi A; Kobayashi S; Suzuki S; Ishihara S; Uchiyama T; Todaka A; Fukutomi A
    Pancreatology; 2020 Oct; 20(7):1519-1525. PubMed ID: 32972834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
    Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
    Trials; 2016 Jan; 17():46. PubMed ID: 26811156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using
    Joshi SS; Catenacci DVT; Karrison TG; Peterson JD; Zalupski MM; Sehdev A; Wade J; Sadiq A; Picozzi VJ; Amico A; Marsh R; Kozloff MF; Polite BN; Kindler HL; Sharma MR
    Clin Cancer Res; 2020 Jan; 26(1):18-24. PubMed ID: 31558477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study.
    Chevalier H; Vienot A; Lièvre A; Edeline J; El Hajbi F; Peugniez C; Vernerey D; Meurisse A; Hammel P; Neuzillet C; Borg C; Turpin A
    Oncologist; 2020 Nov; 25(11):e1701-e1710. PubMed ID: 32886823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.
    Lakatos G; Petranyi A; Szűcs A; Nehéz L; Harsanyi L; Hegyi P; Bodoky G
    Pathol Oncol Res; 2017 Oct; 23(4):753-759. PubMed ID: 28062950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
    Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
    Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
    Conroy T; Gavoille C; Samalin E; Ychou M; Ducreux M
    Curr Oncol Rep; 2013 Apr; 15(2):182-9. PubMed ID: 23341367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Matsumoto I; Kamei K; Omae K; Suzuki S; Matsuoka H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi M; Todaka A; Fukutomi A
    Pancreatology; 2019 Mar; 19(2):296-301. PubMed ID: 30638853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
    Deng B; Jia L; Tan H; Lou Y; Li X; Li Y; Yu L
    J Tradit Chin Med; 2017 Feb; 37(1):35-42. PubMed ID: 29956901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
    Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
    Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of infusional 5-fluorouracil, leucovorin, oxaliplatin and irinotecan in Japanese patients with advanced colorectal cancer who harbor UGT1A1*1/*1,*1/*6 or *1/*28.
    Sunakawa Y; Fujita K; Ichikawa W; Ishida H; Yamashita K; Araki K; Miwa K; Kawara K; Akiyama Y; Yamamoto W; Nagashima F; Saji S; Sasaki Y
    Oncology; 2012; 82(4):242-8. PubMed ID: 22508373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nationwide Multicenter Observational Study of FOLFIRINOX Chemotherapy in 399 Patients With Unresectable or Recurrent Pancreatic Cancer in Japan.
    Todaka A; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Nakamori S; Yachi Y; Henmi T; Kobayashi M; Boku N; Mori K; Fukutomi A
    Pancreas; 2018; 47(5):631-636. PubMed ID: 29683973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.